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Synthesis of 3-(30-indolyl-/30-pyridyl)-isoxazolidines and bis-indoles 331. Introduction
Modiﬁed nucleoside analogs (NAs) having modiﬁed bases were
among the ﬁrst chemotherapeutic agents to be introduced for the
treatment of cancer1–4. Over the years, modiﬁed nucleosides have
expanded the scope of antiviral and anticancer chemotherapeu-
tics5–11. Presently, enormous effort is centered on structural
modiﬁcations of hydroxyl moiety, heterocyclic bases and fur-
anose ring of nucleosides leading to the discovery of a number of
antiviral and anticancer agents12–16. Recently, isoxazolidine
moiety has emerged as valuable analog of the furanose ring
and substituted isoxazolidines have been found to display
valuable antiviral and anticancer properties5,14,15. Indole alka-
loids have also emerged as important candidates for a wide range
of biological activities, including antimicrobial, antiviral and
antitumor17. Various analogs of the natural pimprinine alkaloids
(Fig. 1) are potent inhibitors of HIV-1 integrase. Indole based
molecule is an aromatase inhibitor and has been used to treat
breast cancer. Spiro-indoline-isoxazolidines are known to display
anti-invasive activity against human mammary carcinoma cells18.
Bis-indole derivatives such as bis(indolyl)thiazoles and bis(indo-
lyl)pyrimidines also exhibit cytotoxic activity19,20.
At the same time pyridinyl isoxazolidines (Fig. 2) such as
pyrinodemin-A, chromano-piperidine fused isoxazolidine21 and
pyridinyl-isoxazolidine22,23 exhibit good anticancer activities.
In continuation of our efforts in the search of newer
cytotoxic agents, particularly isoxazolidines15,16, it was decided
to resynthesize the earlier reported 3-pyridyl-/3-indolyl-
isoxazolidines and bis-indoles (17a, 18a-d, 19-21, 23b, 23c, 24,
27a-e, 30, 32 and 33)24 along with some new derivatives (16f, 17d,
23a and 27h) and evaluate their cytotoxic activities against
various human cancer cell lines.2. Results and Discussion
Initially, C-(3-indolyl)-N-phenylnitrone (10) was synthesized
by reacting 3-formylindole and N-phenylhydroxylamine andFigure 1 Some indole ba
Figure 2 Some biologically actcharacterized spectroscopically24. It was reacted with mono-
substituted, disubstituted and cyclic dipolarophiles, and allenic
esters under microwave irradiation leading to the synthesis of
isoxazolidines (16–22) and bis-indole derivatives (23a–c) along
with compounds (24, 25). All compounds (16–25, Scheme 1)
were characterized spectroscopically (1H and 13C NMR, IR
and MS) and microanalytical data24. The structure of com-
pound 21, earlier assigned on the basis of NMR spectral data,
was conﬁrmed by X-ray crystallographic analysis (Fig. 3).
Further, the C-(3-pyridyl)-N-phenylnitrone (26) was
obtained by reacting 3-formylpyridine with N-phenylhydroxy-
lamine in dry benzene and characterized spectroscopically.
It was reacted with mono-substituted, disubstituted and cyclic
dipolarophiles by reﬂuxing in dry toluene for 24–36 h to
obtain, after column chromatographic separation, compounds
27–34. All puriﬁed products (27–34, Scheme 2) were char-
acterized by spectroscopic techniques (1H and 13C NMR, IR
and MS) and microanalytical data25.
All synthesized compounds (16f, 17a, 17d, 18a–d, 19–21, 23a-c,
24, 27a–e, 27h, 29f, 29g, 30, 32 and 33) were evaluated for their
cytotoxic activity against various human cancer cell lines accord-
ing to the protocol of Skehan et al26. Indole-based isoxazolidines
(16–24) were evaluated against various human cancer cell lines
such as cancer of the breast (MCF-7), ovary (IGROV-1), lung (A-
549, HOP-62) and colon (HCT-15 and SW-620). The cytotoxic
effects are reported as percent growth inhibition (Table 1) and
IC50 values (mM, concentration required to inhibit cancer cell
proliferation by 50% after exposure of cells to test compounds)
have also been determined (Table 2); paclitaxel, adriamycin and
mitomycin-C were used as positive controls.
Indole-based isoxazolidines were found to be highly active
against colon and lung cancer cells, moderately active against
ovarian cancer and less active against breast cancer cell.
Initially, compounds (16–24) were evaluated at 100 mM;
however, compounds that showed high cytotoxic activity at
100 mM were further evaluated at concentrations of 50 and
10 mM. Compound 16f showed inhibition of 90% at 100 mM
and 79% at 50 mM against colon cell line (SW-620) with IC50sed anticancer agents.
ive pyridinyl isoxazolidines.
Scheme 1 Synthesis of substituted 3-indolyl-isoxazolidines and bis-indoles.
Vishal Sharma et al.34of 26.6 mM; 86% at 100 mM and 63% at 50 mM against colon
cell line (HCT-15) with IC50 of 32.5 mM; 71% at 100 mM and
66% at 50 mM against lung cell line (A-549) with IC50 of
41.1 mM; 72% at 100 mM and 56% at 50 mM against ovarian
cancer cell line (IGROV-1) with IC50 of 41.4 mM. Compound
17d showed inhibition of 63% at 100 mM and 37% at 50 mM
against colon cell line (SW-620) with IC50 of 74.8 mM.
Compound 18b showed inhibition of 86% at 100 mM and
58% at 50 mM against colon cell line (SW-620) with IC50 of
35.4 mM; 70% at 100 mM and 65% at 50 mM against colon cell
line (HCT-15) with IC50 of 36.8 mM; 74% at 100 mM and 54%
at 50 mM against lung cell line (A-549) with IC50 of 43.4 mM.Compound 18d showed inhibition of 76% at 100 mM and
30% at 50 mM against colon cell line (SW-620) with IC50 of
68.2 mM; 81% at 100 mM and 34% at 50 mM against colon cell
line (HCT-15) with IC50 of 66.1 mM.
Indole derivatives have been reported to suppress the
proliferation of various cancer cell lines at the concentration
range of 50 and 100 mM, including those of breast27–29,
colon30–32, prostate33–35 and endometrium36, by targeting a
wide spectrum of signaling pathways, cell cycle progression
and cell proliferation and survival37–40. Further, it has been
observed that indole-3-carbinol and its metabolite 3,30-diindo-
lylmethane (DIM) inhibit chemical-induced tumorigenesis in
Synthesis of 3-(30-indolyl-/30-pyridyl)-isoxazolidines and bis-indoles 35mammary gland, liver, lung, cervix and gastrointestinal tract
in different animal model studies41–47. Studies using in vitro
models demonstrated that indole derivatives exert anticancer
effects by inhibiting the formation of free radicals, shifting
estrogen metabolism towards the less estrogenic metabolite
2-hydroxyestrone, inducing G1/S arrest of the cell cycle andFigure 3 ORTEP view of 21.
Scheme 2 Synthesis of substituapoptosis, suppressing tumor cell migration, invasion and
angiogenesis48. In clinical trials, indole derivatives have shown
promising efﬁcacy for the prevention of breast cancer, vulvar
intraepithelial neoplasia and human papilloma virus-induced
cervical cancer49–52. These preclinical studies demonstrate the
translational value of indole derivatives in cancer prevention
and therapy34. From the present investigations it emerges that
monosubstituted, 3-indolyl-isoxazolidines (16f, 17a, 17d, 18a–d)
showed better cytotoxic activities than disubstituted compounds
(19, 20) and bicyclic compound (21). Further, it was found that
compounds having X¼–CN, –Ph, and –COCH3, which are
electron withdrawing groups, were found to be more active
against various human cancer cell lines.
Bis-indole derivatives were similarly evaluated against the
human cancer lines; these bis-indoles were mainly active
against colon (HCT-15, SW-620) cancer cells. Compound
23a showed inhibition of 61% at 100 mM and 58% at 50 mM
against colon cell line (SW-620) with IC50 of 39.7 mM.
Compound 23c showed inhibition of 75% at 100 mM and
46% at 50 mM against colon cell line (SW-620) with IC50 of
39.7 mM; 85% at 100 mM and 56% at 50 mM against colon cell
line (HCT-15) with IC50 of 46.6 mM. Although in most of the
cases the exact mechanism of cytotoxic activity is not known
for indole derivatives, isoxazolidines and bis-indoles; however,
the varied modes of action have been reported, which include
the inhibition of NADþ-dependent histone deacetylases53,
inhibition of cyclin dependent kinases54, DNA binding atted 3-pyridyl-isoxazolidines.
Table 1 In vitro cytotoxicity of compounds 16f, 17a, 17d, 18a–d, 19–21, 23a–c and 24 against human cancer cell lines.
Compound No. Conc. (mM) Percent growth inhibition against human cancer cell lines (%)
MCF-7 IGROV-1 A-549 HOP-62 HCT-15 SW-620
16f 10 – 5 9 – 15 10
50 – 56 66 – 63 79
100 – 72 71 – 86 90
17a 100 22 27 – 4 – –
17d 10 – 13 7 – 0 7
50 – 25 24 – 14 37
100 – 58 49 – 54 63
18a 100 39 23 – 51 – –
18b 10 – 5 9 16 15 10
50 – 33 54 – 65 58
100 – 48 74 – 70 86
18c 100 56 43 – 16 – –
18d 10 – 12 7 – 0 10
50 – 27 29 – 34 30
100 – 43 52 – 81 76
19 100 20 21 – 22 – –
20 10 – 0 0 – 3 6
50 – 11 13 – 30 16
100 – 55 54 – 56 39
21 100 11 3 – 6 – –
23a 10 – 0 0 – 16 21
50 – 11 27 – 26 58
100 – 36 40 – 42 61
23b 100 21 23 – 18 – –
23c 10 – 12 – – – 9
50 – 27 30 – 56 46
100 – 62 62 – 85 75
24 100 57 42 – 29 – –
Paclitaxel 10 – 52 59 54 – –
Adriamycin 1 75 – – – 80 70
Mitomycin-C 10 – – 60 – – –
Table 2 IC50 value for the compounds 3-indolyl-isoxa-
zolidines and bis-indoles against various human cancer
cell lines.
Compound No. IC50 (mM)
IGROV-1 A-549 HCT-15 SW-620
16f 41.4 41.1 32.5 26.6
17d 4100 4100 96.3 74.8
18b 4100 43.4 36.8 35.4
18d 4100 94.7 66.1 68.2
20 95 96.4 89.3 4100
23a 4100 4100 43.8 39.7
23c 72.4 75.1 46.6 39.7
Paclitaxel 4.5 4.1 – –
Adriamycin – – 0.1 0.5
Mitomycin-C – 0.4 – –
Vishal Sharma et al.36adinine–thymidine deoxynucleotide rich region in concentra-
tion/substituent manner55, inhibition of topoisomerase I hav-
ing potencies similar to comptothecin56, and inhibition of
tubulin action57.
The cytotoxic activity of pyridine-based isoxazolidines
27(a–e, h), 30, 32, 33 against various human cancer cell linesare reported as percent growth inhibition (Table 3) and IC50
values (Table 4) using paclitaxel, adriamycin and mitomycin-C
as the controls. Compound 27b showed inhibition of 80%
at 100 mM and 41% at 50 mM against lung cancer cell line
(A-549) with IC50 of 72 mM. Compound 27c showed inhibition
of 87% at 100 mM and 80% at 50 mM against human
glioblastoma cell line (SF-295) with IC50 of 38 mM; 76% at
100 mM and 16% at 50 mM against breast cell line (MCF-7);
72% at 100 mM and 45% at 50 mM against lung cell line (A-
549) with IC50 of 64 mM. Compound 29f showed inhibition of
98% at 100 mM and 92% at 50 mM against lung cell line
(HOP-62) with IC50 of 27 mM; 94% at 100 mM, 87% at 50 mM
and 78% at 10 mM against human glioblastoma cell line (SF-
295) with IC50 of 4.35 mM; 82% at 100 mM and 77% at 50 mM
against ovarian cancer cell line (IGROV-1) with IC50 of
35 mM; 84% at 100 mM and 68% at 50 mM against breast
cancer cell line (MCF-7) with IC50 of 54 mM; 79% at 100 mM
and 55% at 50 mM against lung cancer cell line (A-549) with
IC50 of 55 mM.
In general pyridine-based compounds are reported to be
active against various types of cancer such as leukemia, lung,
colon, ovarian, prostate, breast and renal58. Several com-
pounds have been found to exert anticancer action through
the inhibition of protein kinases (CDK1, CDK5 and GSK-3)
while others have shown inhibitory activity against
Table 4 IC50 value for the compounds 3-pyridyl-isoxazolidines against various human cancer cell lines.
Compound No. IC50 (mM)
MCF-7 IGROV-1 A-549 HOP-62 SF-295
27b 90 4100 72 4100 69
27c 4100 51 64 4100 38
29f 54 35 55 27 4.35
Paclitaxel – 4.5 4.1 2.8 –
Adriamycin 0.2 – – – 1
Mitomycin-C – – 0.4 – –
Table 3 In vitro cytotoxicity of compounds 27(a–e, h), 29f, 29g, 30, 32, 33 against human cancer cell lines.
Compound No. Conc (mM) Percent growth inhibition against human cancer cell lines
MCF-7 IGROV-1 A-549 HOP-62 SF-295
27a 100 46 35 39 10 37
27b 10 9 17 5 2 14
50 26 36 41 28 40
100 73 51 80 39 64
27c 10 0 10 2 18 8
50 16 58 45 30 80
100 76 80 72 54 87
27d 100 44 52 34 6 38
27e 100 43 31 16 5 39
27h 100 32 9 13 11 22
29f 10 11 15 10 23 78
50 68 77 55 92 87
100 84 82 79 98 94
29g 100 30 41 22 4 32
30 100 43 19 6 18 26
32 100 27 29 18 7 30
33 100 36 35 13 14 24
Paclitaxel 10 – 52 59 54 –
Adriamycin 1 75 – – – 73
Mitomycin-C 10 – – 60 – –
Synthesis of 3-(30-indolyl-/30-pyridyl)-isoxazolidines and bis-indoles 37topoisomerase I and II59. In the present case, pyridine-based
isoxazolidines 27(a–e, h), 30, 32, 33 were highly active against
ovarian (IGROV-1), breast (MCF-7) and human glioblastoma
(SF-295) cancer cells. Based on the observed cytotoxic activity
of 3-pyridyl-isoxazolidines against various human cancer cell
lines, it was observed that monosubstituted, 3-pyridyl-isoxa-
zolidines (27a–e, 27h, 29f, 29g) showed better cytotoxic
activity than disubstituted compounds (30, 32) and cyclic
compound (33). Further, it was found that compounds having
X¼–Ph, and COCH3 were found to be more active against
human cancer cell lines than others. Cytotoxic results also
reveal that the compounds having syn isomeric form showed
better activity than trans form, and that 29f, as the only single
dominant regioisomer formed with trans orientation, was
active against human cancer cell lines such as breast, lung,
CNS and ovary.3. Conclusions
A variety of substituted 3-pyridyl-/3-indolyl-isoxazolidine
and bis-indole derivatives were synthesized by reaction of nitrones
with various oleﬁnic/allenic dipolarophiles. The major isomers,some minor isomers and bis-indoles obtained were evaluated for
their cytotoxic activities against various human cancer cell lines.
Some of the compounds display signiﬁcant cytotoxic activities
against various human cancer cell lines. For instance, 3-indolyl-
isoxazolidine 16f and 18b are active against the ovarian, lung and
colon cancer cell lines, whereas, 3-pyridyl-isoxazolidines 27c is
active against glioblastoma cells and compound 29f is active
against breast, lung, glioblastoma and ovarian cancer cell lines.
Bis-indole derivatives 23a and 23c are active against colon. These
‘lead’ compounds can be used for further anticancer drug
development and their mode of action studies.4. Experimental
4.1. General methods
Starting materials and reagents were purchased from com-
mercial suppliers and used after further puriﬁcation (crystal-
lization/distillation). Bruker AC-200 FT (200 MHz) and JEOL
(300 MHz) NMR spectrophotometer were used for recorded
the 1H and 13C NMR (75 MHz) Chemical shifts are reported
in ppm, tetramethylsilane used as the internal standard and
Vishal Sharma et al.38J values in Hertz. IR spectra were recorded on Shimadzu
8400S FT-IR spectrophotometer (KBr. cm–1). Mass spectra,
EI and ESI methods, were recorded on Shimadzu GCMS-QP-
2000A and Bruker Daltonics Esquire 300 mass spectrometers,
respectively. Elemental analyses were carried out on a Ther-
moelectron EA-112 elemental analyzer and are reported in
percent atomic abundance. All melting points are uncorrected
and measured in open glass capillaries using Veego Precision
Digital Melting Point Apparatus. X-ray analysis was recorded
at Bruker SMART APEX diffractometer equipped with low-
temperature device and the structure was solved by direct
methods using SHELXS 97 software.
4.2. Chemistry
4.2.1. Synthesis of C-(3-Indolyl)-N-phenylnitrone (10)
3-Formylindole (2.8 mmol) was dissolved in dry ethanol
(30 mL) to the clear solution. N-phenyl-hyroxylamine hydro-
chloride (2.8 mmol) was added and the contents were allowed
to stand at room temperature overnight. Solvent was evapo-
rated under vacuum to obtain the viscous yellow oil, which
was crystallized in chloroform–ether (1:2) to obtain nitrone as
a light yellow powder (yield 90%). The nitrone (10) was dried
under vacuum and stored under refrigeration24.
4.2.2. General procedure for microwave irradiation of
C-(3-indolyl)-N-phenylnitrone (10) with various dipolarophiles
Mixture of C-(3-indolyl)-N-phenylnitrone (10, 1.28 mmol) and
various dipolarophiles (11, 12, 13, 14, 1.0 equ.) were dissolved
in a 50-mL conical ﬂask and the contents was placed in the
cavity of the microwave reactor and irradiated. Progress of
completion of reaction was monitored by TLC. After the
completion of reaction, the residues were loaded onto silica
(60–120, mesh column packed in hexane); elution of column
using hexane-chloroform (gradient) afforded the pure pro-
ducts. The reported yields are based on isolated pure products
and relative proportions determined in the mixtures by 1H
NMR spectroscopy24.
4.2.3. General procedure for microwave irradiation of
C-(3-Indolyl)-N-phenylnitrone (10) with various allenic esters
In a 150-mL round bottom ﬂask, the C-(3-indolyl)-N-phenyl-
nitrone (10, 1.28 mmol) and allenic esters (15a–d, 1.0 equ.)
were added, and ﬂask was ﬁtted with a condenser in the cavity
of the microwave reactor. After closing the cavity of the
reactor with the cavity lid, the contents were irradiated (150W,
100 1C) for 3 min (1 min hold time and 2 min running time) till
all the nitrone was consumed as monitored by TLC. After
completion of the reaction, the residues were loaded onto
silica gel column (60–120 mesh, column packed in hexane);
elution of column using hexane–chloroform (gradient)
afforded the pure products. The reported yields are based on
isolated pure products and relative proportions determined in
the mixtures by 1H NMR spectroscopy24.
4.2.4. Synthesis of C-(3-Pyridyl)-N-phenylnitrone (26)
3-Formylpyridine (3.0 g, 2.8 mmol) was dissolved in dry
benzene (30 mL) and to the clear solution. N-Phenyl-hydro-
xylamine hydrochloride (4.08 g, 2.8 mmol) was added and the
contents were allowed to stand at room temperature, after30 min nitrone (26) precipitated out as a light yellow solid,
which was ﬁltered (5.2 g, 95%). mp 86–88 1C.
4.2.5. General procedure for the reaction of nitrone (26) with
various dipolarophiles
Reactions of nitrone with various dipolarophiles were carried
out by mixing nitrone (26, 1.5 mmol) with dipolarophiles
(11, 12, 13, 14, 1 equ.) in a dry toluene (50 mL) and reaction
mixtures were reﬂuxed with constant stirring, until all the
nitrone was consumed. After the completion of reactions as
monitored by TLC, the solvent was completely removed under
reduced pressure. The products were puriﬁed by column
chromatography (silica gel 60–120 mesh, 20 g, column packed
in hexane). The reported yields are based on isolated pure
products and relative proportions determined in the mixture
by 1H NMR spectroscopy.
4.3. Characterization of new products
4.3.1. Anti-30-(2,5-diphenyl-isoxazolidin-3-yl)-1-H-indole
(16f)
Colorless solid; Yield (400 mg, 80%), mp. 168–170 1C; IR
(CHCl3): 3369, 3190, 2879, 1645, 1590, 1456, 1456, 1433, 1268,
767 cm1; 1H NMR (CDCl3, 300 MHz): d 8.03 (br, s, 1H,
NH), 7.65 (d, 1H, J¼8.1 Hz, C40H), 7.41–6.86 (m, 14H,
Ar–Hs), 5.23–5.14 (m, 2H, C3H & C5H), 3.22 (ddd,
Jgem¼12.9 & J¼7.2, 1.5 Hz, C4Ha), 2.61 (ddd, Jgem¼12.9 &
J¼4.8, 2.1 Hz C4Hb); 13C NMR (CDCl3, 75 MHz): d 150.2
(q), 148.7 (q), 135.9 (C70a), 131.6 (C30a), 128.9 (CH), 126.9
(CH), 126.7 (CH), 125.4 (CH), 122.4 (CH), 122.3 (C20), 121.5
(C50), 121.3 (C40), 119.7 (C60), 116.1 (CH), 114.2 (C30), 111.3
(C70), 80.4 (C5), 65.7 (C3), 46.7 (C4). MS (ESI) m/z: 340 [M]þ;
Anal. Calcd. for C23H22N2O: C 81.45; H 5.90; N 8.20. Found:
C 81.49; H 5.95; N 8.90.
4.3.2. Syn-30-(2-phenyl-5-pyridin-4-yl-isoxazolidin-3-yl)-1-H-
indole (17d)
Light brown viscous oil (375 mg, 75%); IR (CHCl3): 3257,
3062, 2923, 2852, 1650, 1596, 1494, 1438, 1377, 1244,
752 cm1; 1H NMR (CDCl3, 300 MHz): d 8.29 (br, s, 1H,
NH), 7.50–7.25 (m, 15H, Ar–Hs), 5.30 (d, 1H, J¼8.1 Hz,
C3H), 4.55 (dd, 1H, Jgem¼10.1 & J¼6.2 Hz, C5Ha), 4.39 (dd,
1H, Jgem¼10.1 & J¼8.4 Hz, C5Hb), 3.38 (unresolved dd,
J8.1 & 5.7 C4H); 13C NMR (CDCl3, 75 MHz): 157.4 (q),
152.8 (CH), 150.4 (q), 139.1 (C70a), 129.2 (C30a), 128.7 (CH),
125.6 (CH), 124.0 (C20), 123.4 (CH), 122.7 (C50), 122.4 (C60),
121.8 (C40), 115.1 (CH), 114.2 (C30), 111.7 (C70), 89.4 (C5),
68.4 (C3), 49.4 (C4). MS (ESI) m/z: 341 [M]þ; Anal. Calcd. for
C22H19N3O: C 77.40; H 5.61; N 12.31. Found: C 77.43; H
5.64; N 12.35.
4.3.3. Anti-1-[3-(1H-indol-30-yl)-4-methyl-2-phenyl-
isoxazolidin-4-yl]-ethanone (18e)
Brownish viscous oil (400 mg, 80%); IR (CHCl3): 3343, 3292,
2927, 2856, 2362, 1713, 1653, 1532, 1489, 1429, 1362, 1244,
746 cm1; 1H NMR (CDCl3, 300 MHz): d 8.16 (br, s, 1H,
NH), 7.79 (d, 1H, J¼3.0 Hz, Ar-H), 7.37–7.00 (m, 9H,
Ar–Hs), 5.06 (d, 1H, J¼5.4 Hz, C3H), 4.46 (dd, 1H,
Jgem¼10.6 & J¼3.4 Hz, C5Ha), 4.29 (dd, 1H, Jgem¼10.6 &
J¼8.6 Hz, C5Hb), 3.85 (unresolved dd, J6.9 & 3.4 C4H),
2.16 (s, 1H, CH3);
13C NMR (CDCl3, 75 MHz): 204.4 (C¼O),
Synthesis of 3-(30-indolyl-/30-pyridyl)-isoxazolidines and bis-indoles 39150.2 (q), 136.9 (C70a), 129.0 (C30a), 128.6 (CH), 125.3 (CH),
122.7 (C20), 122.6 (C50), 120.9 (C40), 119.6 (C60), 116.1 (C30),
115.5 (CH), 111.4 (C70), 68.2 (C5), 66.1 (C3), 64.7 (C4), 29.6
(CH3). MS (ESI) m/z: 306 [M]
þ; Anal. Calcd. for C19H18N2O2:
C 74.49; H 5.92; N 9.14. Found: C 74.52; H 5.94; N 9.16.
4.3.4. 2-(1 H-Indol-20-yl)-3-(1 H-indol-3-yl)-acrylic acid
ethyl ester (23a)
Brown viscous oil, yield (360 mg, 72%); IR (CHCl3): 3375,
3056, 2927, 1654, 1596, 1458, 1242, 746 cm1; 1H NMR
(CDCl3, 300 MHz): d 8.20 (s, 1H, C8H), 8.14 (br, s, 1H,
NH), 7.80 (unresolved dd, 2H, J¼7.8 Hz, Ar–Hs), 7.52 (br, s,
1H, NH), 7.447.02 (m, 7H, Ar-Hs), 6.00 (d, 1H, J¼2.4 Hz,
C2H), 4.04(q, 2H, J¼7.2 Hz, OCH2), 1.14 (t, 3H, J¼7.2 Hz,
OCH3);
13C NMR (CDCl3, 75 MHz): d 167.7 (C¼O), 136.9
(C8), 136.8 (C9), 136.2 (C70a), 135.9 (C7a), 128.1 (C30a),
127.0(C3a), 124.6 (C20), 124.4 (C2), 122.8 (C40), 121.7 (C4),
119.6 (C5), 118.7 (C50), 117.8 (C60), 117.4 (C6), 111.7 (C70),
111.3 (C7), 98.0 (C3), 63.29 (–OCH2), 13.9 (CH3). MS (ESI)
m/z : 330.3 [M]þ; Anal. Calcd. for C21H18N2O2: C 76.34; H
5.49; N 8.48. Found: C 76.35; H 5.54; N 8.50.
4.3.5. Syn-5-hydroxymethyl-2-phenyl-3-(30-pyridyl)-
isoxazolidine (27h)
Light brown viscous oil (350 mg, 70%). IR nmax (CHCl3):
3410, 3396, 3043, 2922, 2246, 1596, 1489, 1453.9, 1427, 1322,
1261, cm1; 1H NMR (CDCl3, 300 MHz): d¼8.67(br s, 1H,
Ar–H), 8.51(d, 1H, J¼8.1 Hz, Ar–H), 7.87(d, 1H, J¼8.1 Hz,
Ar–H), 7.30-7.16(m, 3H, Ar-H), 7.016.93(m, 3H, Ar–H),
4.81(dd, J¼8.1 & 6.3 Hz, C3H), 4.48(dd, J¼5.4 & 3.0 Hz,
C5H), 3.75-3.66(m, 2H, CH2OH), 3.37(br, s, 1H, OH), 2.48
(ddd, 1H, Jgem¼12.6 Hz and J¼8.1 & 5.6 Hz, C4Ha), 2.04
(ddd, 1H, Jgem¼12.6 Hz and J¼5.8 & 3.0 Hz, C4Hb);
13C NMR (CDCl3, 75 MHz): d 150.06(C20), 148.4(C60),
148.1(q), 138.1(C30), 134.4(C40), 128.8(CH), 123.7(C50),
122.3(CH), 115.7(CH), 68.2(C3), 62.5(C5), 58.1(CH2OH)
49.3(C4). MS (ESI) m/z : 256 [M]þ ; Anal. Calcd. For
C15H16N2O2: C 75.56; H 7.13; N 11.01. Found: C 67.24; H
5.41; N 10.99.
4.4. Cytotoxic activity
For the evaluation of cytotoxicity, the compounds were
dissolved in DMSO and stock solutions of 2 104 mM were
prepared. Stock solutions were further diluted with complete
growth medium supplemented with 50 mg/mL gentamicin to
obtain test concentrations of 10, 50 and 100 mM. Adriamycin
and paclitaxel were dissolved in DMSO and stock solutions of
2 103 mM were prepared. Mitomycin-C was dissolved in
double distilled water and a stock solution of 2 103 mM
was prepared. All cells were maintained in RPMI-1640
medium, supplemented with fetal bovine serum (10%),
100 units/mL penicillin and 100 mg/mL streptomycin (com-
plete medium). The cells were seeded into 96 well cell culture
plates (1 104 cells/100 mL/well) and incubated in CO2 incu-
bator (37 1C, 5% CO2, 95% relative humidity) for 24 h. After
24 h, compounds 16f, 17a, 17d, 18a–d, 19–21, 23a–c, 24, 27a–e,
29f, 29g, 30, 32, 33, and positive controls (100 mL/well) were
added in quadruplets and the plates were further incubated in
CO2 incubator for 48 h. Suitable controls were also included
in each experiment. After 48 h chilled trichloro acetic acid(50% w/v, 50 mL) was laid gently on top of the medium in all
the wells. The plates were incubated at 4 1C for 1 h to ﬁx the
cells. All the contents of the wells were gently pipetted out and
discarded. The plates were washed ﬁve times with distilled
water to remove trichloro acetic acid, growth medium, low
molecular weight metabolites and serum proteins etc. The
plates were air-dried. Sulphorhodamine-B (0.4% SRB in 1%
acetic acid, 100 mL/well) was added to each well of the 96 well
plates for 30 min. Excess of the dye was washed off using 1%
acetic acid and the plates were air-dried. Tris buffer (10 mM,
pH 10.5, 100 mL/well) was added to each well and plates were
shaken on a mechanical stirrer for 10 min and optical density
was recorded on an ELISA reader at 540 nm. Viability of cells
was evaluated by trypan blue exclusion method immediately
before setting up the experiment for cytotoxicity determina-
tion. Cells with 498% viability were used in the assay.Acknowledgments
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